IBA seeks FDA approval for proton therapy gantry system

Radiopharmaceutical firm IBA Molecular has submitted documentation to the U.S. Food and Drug Administration (FDA) for a compact proton therapy gantry.

The submission includes full documentation from recently completed in-factory performance and safety tests of its compact gantry beam line. The compact gantry beam line has already been shipped to Willis-Knighton Cancer Center (WKCC) as an element of the first Proteus One system.

Three Proteus One systems have been ordered to date, with patient treatment expected to start in 2014.

Page 1 of 551
Next Page